Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 426Carcinoma, Non-Small-Cell Lung 92Neoplasm Metastasis 69Neoplasms 60Carcinoma, Renal Cell 54Lymphoma, T-Cell, Cutaneous 52Ovarian Neoplasms 46Squamous Cell Carcinoma of Head and Neck 42Breast Neoplasms 40Colorectal Neoplasms 38Stomach Neoplasms 37Skin Neoplasms 35Lymphoma 32Uveal Melanoma 31Mycosis Fungoides 31Carcinoma, Merkel Cell 31Triple Negative Breast Neoplasms 29Lung Neoplasms 29Sezary Syndrome 28Lymphoma, Non-Hodgkin 28Lymphoma, Follicular 27Hodgkin Disease 27Pancreatic Neoplasms 26Uterine Cervical Neoplasms 25Sarcoma 25Lymphoma, Large B-Cell, Diffuse 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, B-Cell, Marginal Zone 23Carcinoma, Hepatocellular 23Lymphoma, Mantle-Cell 22

Interventions

imisopasem manganese 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hypotension × Dermatologic × Clear all
NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡